Document Detail

Recipients potentially infected with parvovirus B19 by red blood cell products.
MedLine Citation:
PMID:  20663115     Owner:  NLM     Status:  In-Process    
BACKGROUND: Since 2000, blood donor screening for parvovirus B19 (B19) by nucleic acid testing (NAT) at the Ulm Institute has been conducted 6 to 8 weeks postdonation, that is, after transfusion of cellular blood products, whereas at the Frankfurt Institute all donations are screened before releasing any blood product. In this study, we evaluated the infectivity of B19-positive blood products in relation to the virus concentration in the transfused blood component.
STUDY DESIGN AND METHODS: Recipients were classified into two groups (A, transfused with blood products with B19 virus load less than 10(5) IU/mL; and B, transfused with blood products with B19 virus load greater than 10(5) IU/mL). Phylogenetic analyses were done for B19 DNA-positive donor and recipient pairs in the variant VP-1u genome region. All samples were investigated for immunoglobulin (Ig)M and IgG B19 antibodies.
RESULTS: B19 DNA was detected in 9 of 18 recipients of red blood cells (RBCs) from Group B, whereas none of the 16 recipients of RBCs from Group A were positive for B19 DNA (p=0.016). Phylogenetic analysis demonstrated identical genomic sequences between the donors and recipients. Because recipient B19 DNA and antibody results were not available before transfusion, we interpret our overall data to indicate equivocal evidence of B19 transmission by RBC transfusion.
CONCLUSION: B19 transmission by cellular blood products correlates with the virus concentration and the concentration of neutralizing antibodies. Thus, blood donor screening for B19 by minipool NAT should be done to supply at-risk patients (e.g., immunosuppressed patients) with B19-negative blood components.
Michael Kai Hourfar; Uschi Mayr-Wohlfart; Anna Themann; Walid Sireis; Erhard Seifried; Hubert Schrezenmeier; Michael Schmidt
Related Documents :
17345745 - A flow reactor process for the synthesis of peptides utilizing immobilized reagents, sc...
2022395 - Hiv antibody screening of commercially available blood products in india.
19901625 - Progress in global blood safety for hiv.
3041385 - Ddavp in the treatment of bleeding disorders.
22918965 - Frontal information flow and connectivity in psychopathy.
11788355 - Plasma l-5-oxoproline kinetics and whole blood glutathione synthesis rates in severely ...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Transfusion     Volume:  51     ISSN:  1537-2995     ISO Abbreviation:  Transfusion     Publication Date:  2011 Jan 
Date Detail:
Created Date:  2011-01-11     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0417360     Medline TA:  Transfusion     Country:  United States    
Other Details:
Languages:  eng     Pagination:  129-36     Citation Subset:  IM    
Copyright Information:
© 2010 American Association of Blood Banks.
Institute for Transfusion Medicine and Immunohematology, Johann Wolfgang Goethe University, German Red Cross, Baden-Württemberg-Hessen, Institute Frankfurt, Frankfurt, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Persistence of lymphocyte function perturbations after granulocyte-colony-stimulating factor mobiliz...
Next Document:  Toward a definition of "fresh" whole blood: an in vitro characterization of coagulation properties i...